Pteridines useful as HCV inhibitors and methods for the preparation thereof
US-9290502-B2 · Mar 22, 2016 · US
Pteridines useful as HCV inhibitors and methods for the preparation thereof
US9708328B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9708328-B2 |
| Application number | US-201615047038-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 18, 2016 |
| Priority date | May 12, 2005 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the formula (VII): or a salt, stereoisomeric form, or racemic mixture thereof, wherein R 1 is hydrogen; R 8 is hydrogen and R 9 is —CONR 4a R 4b ; or R 8 is phenylC 1-4 alkyl and R 9 is hydrogen; R 4a is hydrogen; and R 4b is 2-oxo-pyrrolidin-1-yl-C 1-4 alkyl. 2. The compound according to claim 1 of the formula (VIII): 3. The compound according to claim 2 , wherein R 8 is phenylC 1-4 alkyl and R 9 is hydrogen. 4. The compound according to claim 1 that is 5. The compound according to claim 1 that is 6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient. 7. The pharmaceutical composition according to claim 6 , further comprising one or more other anti-hepatitis C virus agents.
Assignees
Inventors
Classifications
Antivirals · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for RNA viruses · CPC title
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9708328B2 cover?
- The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising t…
- Who is the assignee on this patent?
- Janssen Sciences Ireland Uc
- What technology area does this patent fall under?
- Primary CPC classification C07D475/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).